A Review of the Therapeutic Management of Ulcerative Colitis

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2022 Dec 8

PMID 36478780

Authors

Nasar Aslam

Sheng Wei Lo

Rafid Sikafi

Tom Barnes

Jonathan Segal

Philip J Smith

Jimmy K Limdi

Affiliations

Soon will be listed here.

Abstract

Ulcerative colitis (UC) is a chronic relapsing and remitting gastrointestinal disorder of uncertain aetiology. The last two decades have seen an expansion in the therapeutic arsenal used to treat UC. This has resulted in improved clinical remission and response rates. Nonetheless, staples in our current medical management originate from trials conducted in the early 20th century. In this review article, we aim to outline the key milestones in the history of the medical management of UC in addition to highlighting promising therapeutic developments for the future.

Citing Articles

Comparative Effects of Probiotics and Paraprobiotics Derived from , , and in a DSS-Induced Ulcerative Colitis Mouse Model.

Kang Y, Song H, Park S, Oh D, Kim G, Been N J Microbiol Biotechnol. 2025; 35:e2411045.

PMID: 40016142 PMC: 11896797. DOI: 10.4014/jmb.2411.11045.

Preclinical Long-Term Stability and Forced Degradation Assessment of EPICERTIN, a Mucosal Healing Biotherapeutic for Inflammatory Bowel Disease.

Kittle W, Reeves M, Fulkerson A, Hamorsky K, Morris D, Kitterman K Pharmaceutics. 2025; 17(2).

PMID: 40006626 PMC: 11859197. DOI: 10.3390/pharmaceutics17020259.

A practical approach to positioning therapies in ulcerative colitis.

Yanofsky R, Rubin D J Can Assoc Gastroenterol. 2025; 8(Suppl 2):S6-S14.

PMID: 39990515 PMC: 11842905. DOI: 10.1093/jcag/gwae058.

Mucosal Bacterial Immunotherapy Attenuates the Development of Experimental Colitis by Reducing Inflammation Through the Regulation of Myeloid Cells.

Jimenez E, Vazquez A, Gonzalez S, Sacedon R, Fernandez-Sevilla L, Varas A Int J Mol Sci. 2025; 25(24.

PMID: 39769391 PMC: 11728189. DOI: 10.3390/ijms252413629.

Exploring Immune Cell Infiltration and Small Molecule Compounds for Ulcerative Colitis Treatment.

Lu Y, Lu D, Li C, Chen L Genes (Basel). 2025; 15(12).

PMID: 39766817 PMC: 11728156. DOI: 10.3390/genes15121548.

References

Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J . Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012; 380(9857):1909-15. DOI: 10.1016/S0140-6736(12)61084-8. View

Hanauer S, Sandborn W, Kornbluth A, Katz S, Safdi M, Woogen S . Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005; 100(11):2478-85. DOI: 10.1111/j.1572-0241.2005.00248.x. View

Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J . Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018; 113(9):1345. PMC: 6445254. DOI: 10.1038/s41395-018-0162-0. View

Azad Khan A, Piris J, TRUELOVE S . An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977; 2(8044):892-5. DOI: 10.1016/s0140-6736(77)90831-5. View

Caprilli R, Clemente V, Frieri G . Historical evolution of the management of severe ulcerative colitis. J Crohns Colitis. 2010; 2(3):263-8. DOI: 10.1016/j.crohns.2008.03.008. View

Reinisch W, Sandborn W, Hommes D, DHaens G, Hanauer S, Schreiber S . Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011; 60(6):780-7. DOI: 10.1136/gut.2010.221127. View

Fine S, Papamichael K, Cheifetz A . Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2020; 15(12):656-665. PMC: 6935028. View

Rubin D, Cohen R, Sandborn W, Lichtenstein G, Axler J, Riddell R . Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017; 11(7):785-791. PMC: 5881669. DOI: 10.1093/ecco-jcc/jjx032. View

Dew M, Ryder R, Evans N, Evans B, Rhodes J . Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis. Br J Clin Pharmacol. 1983; 16(2):185-7. PMC: 1427967. DOI: 10.1111/j.1365-2125.1983.tb04983.x. View

10.

Dhillon S, Keam S . Filgotinib: First Approval. Drugs. 2020; 80(18):1987-1997. PMC: 7858213. DOI: 10.1007/s40265-020-01439-0. View

11.

Haifer C, Paramsothy S, Kaakoush N, Saikal A, Ghaly S, Yang T . Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2021; 7(2):141-151. DOI: 10.1016/S2468-1253(21)00400-3. View

12.

Miyake N, Ando T, Ishiguro K, Maeda O, Watanabe O, Hirayama Y . Azathioprine is essential following cyclosporine for patients with steroid-refractory ulcerative colitis. World J Gastroenterol. 2015; 21(1):254-61. PMC: 4284343. DOI: 10.3748/wjg.v21.i1.254. View

13.

Williams J, Alam M, Alrubaiy L, Arnott I, Clement C, Cohen D . Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016; 1(1):15-24. PMC: 4994668. DOI: 10.1016/S2468-1253(16)30003-6. View

14.

Macaluso F, Cummings J, Atreya R, Choi J, Orlando A . A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence. Expert Opin Biol Ther. 2021; 22(2):203-223. DOI: 10.1080/14712598.2021.1958778. View

15.

Timmer A, Patton P, Chande N, McDonald J, MacDonald J . Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016; (5):CD000478. PMC: 7034525. DOI: 10.1002/14651858.CD000478.pub4. View

16.

Sandborn W, Van Assche G, Reinisch W, Colombel J, DHaens G, Wolf D . Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2011; 142(2):257-65.e1-3. DOI: 10.1053/j.gastro.2011.10.032. View

17.

Wasserbauer M, Hlava S, Drabek J, Stovicek J, Minarikova P, Nedbalova L . Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring. PLoS One. 2022; 17(8):e0271299. PMC: 9359532. DOI: 10.1371/journal.pone.0271299. View

18.

Barberio B, Segal J, Quraishi M, Black C, Savarino E, Ford A . Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. J Crohns Colitis. 2021; 15(7):1184-1196. DOI: 10.1093/ecco-jcc/jjab010. View

19.

Allamneni C, Venkata K, Yun H, Xie F, DeLoach L, Malik T . Comparative Effectiveness of Vedolizumab vs. Infliximab Induction Therapy in Ulcerative Colitis: Experience of a Real-World Cohort at a Tertiary Inflammatory Bowel Disease Center. Gastroenterology Res. 2018; 11(1):41-45. PMC: 5827901. DOI: 10.14740/gr934w. View

20.

Sandborn W, Rebuck R, Wang Y, Zou B, Adedokun O, Gasink C . Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2021; 20(3):578-590.e4. PMC: 8374005. DOI: 10.1016/j.cgh.2021.02.025. View